Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients
ST. LOUIS, Sept. 8 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) highlighted significant new additions to the body of evidence demonstrating exceptional clinical outcomes achieved with its Niobe® Magnetic Navigation System in ventricular tachycardia (VT) ablation.
At the European Cardiology Society Annual Congress in Stockholm last week, the research team led by Dr. Tamas Szili-Torok from the Erasmus Medical Center in Rotterdam presented the first comparative trial in a prospective study of 64 consecutive VT patients, comparing Stereotaxis VT ablation to conventional, non-magnetic ablation. Acute success was achieved in 97% of the Stereotaxis VT ablation group versus 81% of the manual ablation group. Patients in the Stereotaxis VT group averaged 50% less x-ray exposure, and after a year, only 14% VT recurrence, versus a 50% recurrence rate among manual ablation patients. A remarkable 25% reduction in total procedure time was achieved in the Stereotaxis VT group compared to the manual group.
There were no major complications in the Stereotaxis VT group compared to one death in the non-Stereotaxis group, representing a 4% major complication rate.
"The use of Stereotaxis offers major advantages for the ablation of VT," said Dr. Szili-Torok. "We have adopted a 100% utilization rule for our Stereotaxis lab for cardiac arrhythmias due to the significant benefits for our patients as well as for us as operators."
Further, Dr. Arash Arya and colleagues from the University of Leipzig Heart Center in Leipzig, Germany published data from a series of 30 consecutive patients who were suffering from "VT storm," which is three or more VT episodes in a 24 hour period that trigger a shock treatment from an implanted defibrillator device. While treating VT Storm is extremely challenging, Dr. Arya reported that 70% of the patients